We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Differential Gene Expression Aids Disseminated Tumor Cells Adapt to Diverse Microenvironments

By LabMedica International staff writers
Posted on 09 Nov 2015
A recent paper described how cancer cells that have broken away from a primary tumor are able to establish the conditions they need to survive in a distant site that possesses a quite different microenvironment.

Investigators at the University of Notre Dame (South Bend, IN, USA) and at the University of Texas MD Anderson Cancer Center (Houston, USA) reported in the October 19, 2015, online edition of the journal Nature that the ability of disseminated tumor cells to establish themselves in distant locations was dependent on expressing or silencing the tumor suppressor gene PTEN.

PTEN (phosphatase and tensin homolog) is one of the most commonly lost tumor suppressors in human cancer. More...
During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer. When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in both cell movement and adhesion of cells to surrounding tissues.

The investigators found that both human and mouse tumor cells with normal expression of PTEN lost expression of this gene after dissemination to the brain, but not to other organs. The PTEN level in PTEN-loss brain metastatic tumor cells was restored after leaving the brain microenvironment. This brain microenvironment-dependent, reversible PTEN messenger RNA and protein downregulation was epigenetically regulated by microRNAs from brain astrocytes.

Astrocyte-derived exosomes mediated an intercellular transfer of PTEN-targeting microRNAs to metastatic tumor cells, while astrocyte-specific depletion of PTEN-targeting microRNAs or blockade of astrocyte exosome secretion rescued the PTEN loss and suppressed brain metastasis in vivo. This adaptive PTEN loss in brain metastatic tumor cells led to an increased secretion of the chemokine CCL2, which recruited myeloid cells that reciprocally enhanced the outgrowth of brain metastatic tumor cells via enhanced proliferation and reduced apoptosis.

Contributing author Dr. Siyuan Zhang, professor of cancer research at Notre Dame University, said, "The microenvironment has tremendous impact on how the gene is expressed, what type of gene will be expressed. It is definitely not due to genetic mutation. The point of this paper is we should not overlook the huge influence of the tissue architecture, the tissue environment, the tissue composition. It is a dynamic process."

Related Links:

University of Notre Dame
University of Texas MD Anderson Cancer Center 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Electrolyte Analyzer
BKE-B
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: The method combines metagenomic sequencing with computational filtering to identify likely disease-causing bacteria and viruses (Image Credit: iStock)

Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis

Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.